May is Arthritis Awareness Month: Understanding Inflammatory Arthritis

Did you know May is Arthritis Awareness Month?

Arthritis comes in various forms, many of which are inflammatory in nature. Early intervention is crucial to manage inflammation and prevent further joint damage. This is particularly vital as some types of inflammatory arthritis can affect not only joints but also internal organs.

Inflammatory arthritis can impact the entire body, earning its classification as systemic. Among the most prevalent forms are rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). Children can also be affected by inflammatory arthritis.

Let's raise awareness and support those affected by arthritis this month and beyond. Together, we can work towards better understanding, treatment, and support for this challenging condition.

While focusing on endometriosis, Gesynta Pharma sees potential for potent and selective mPGES-1 inhibitors also in providing better treatments for arthritis patients.

Learn more about inflammatory arthritis: https://www.ncbi.nlm.nih.gov/books/NBK507704/


Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.